Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 2Urogenital Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Genital Neoplasms, Male 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 5Gemcitabine 4Albumin-Bound Paclitaxel 4Trastuzumab 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3pazopanib 2Taxes 2Sorafenib 2Radiotherapy 2Radiation 2Paclitaxel 2N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 2Lapatinib 2Doxorubicin 2Docetaxel 2Capecitabine 2romidepsin 1rV-Tricom 1peginterferon alfa-2a 1pegfilgrastim 1oblimersen 1methyl N-acetylsibirosaminide 1ixabepilone 1fludarabine phosphate 1fludarabine 1exemestane 1cediranib 1alvocidib 1Zoledronic Acid 1Whole-Body Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms, Male × Suspensions × Clear all
NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NantBioScience, Inc.

Phase 1 Terminated
3 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡